Skip to main content
European Commission logo print header

Development of an efficacious vaccine against animal brucellosis that is harmless for humans

Obiettivo

Currently available live vaccines used for medical prophylaxis of brucellosis present serious side effects, which restrict their use and require good managing procedures for sanitary authorities and the farmer to obtain a definitive eradication. The most crucial of these drawbacks is that the live vaccines, whilst attenuated, still remain fully virulent for man. In addition, the vaccination is not fully efficacious and interferes with the diagnosis of field infection. Because of the continuing European incidence of brucellosis in animals and man, the development of a safe and efficacious vaccine that do not possess these disadvantages but which does stimulate protective immunity against the major pathogens of the genus Brucella is highly desirable and justified. The objectives of the proposal are to obtain well defined (rationally) attenuated vaccine strains or an efficient DNA vaccine that are immunologically distinguishable from natural infection and do not present the drawbacks if of existing vaccines.

Invito a presentare proposte

Data not available

Meccanismo di finanziamento

CSC - Cost-sharing contracts

Coordinatore

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Contributo UE
Nessun dato
Indirizzo
Rue de Tolbiac, 101
75654 PARIS
Francia

Mostra sulla mappa

Costo totale
Nessun dato

Partecipanti (5)